Lobelia chinensis Extract and Its Active Compound, Diosmetin, Improve Atopic Dermatitis by Reinforcing Skin Barrier Function through SPINK5/LEKTI Regulation
Rattachement africain : kr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The skin acts as a mechanical barrier that protects the body from the exterior environment, and skin barrier function is attributed to the stratum corneum (SC), which is composed of keratinocytes and skin lipids. Skin barrier homeostasis is maintained by a delicate balance between the differentiation and exfoliation of keratinocytes, and keratinocyte desquamation is regulated by members of the serine protease kalikrein (KLK) family and their endogenous inhibitor SPINK5/LEKTI (serine protease inhibitor Kazal type 5/lympho-epithelial Kazal-type-related inhibitor). Furthermore, SPINK5/LEKTI deficiency is involved in impaired skin barrier function caused by KLK over-activation. We sought to determine whether increased SPINK5/LEKTI expression ameliorates atopic dermatitis (AD) by strengthening skin barrier function using the ethanol extract of Lobelia chinensis (LCE) and its active compound, diosmetin, by treating human keratinocytes with UVB and using a DNCB-induced murine model of atopic dermatitis. LCE or diosmetin dose-dependently increased the transcriptional activation of SPINK5 promoter and prevented DNCB-induced skin barrier damage by modulating events downstream of SPINK5, that is, KLK, PAR2 (protease activated receptor 2), and TSLP (thymic stromal lymphopoietin). LCE or diosmetin normalized immune response in DNCB treated SKH-1 hairless mice as determined by reductions in serum immunoglobulin E and interleukin-4 levels and numbers of lesion-infiltrating mast cells. Our results suggest that LCE and diosmetin are good candidates for the treatment of skin barrier-disrupting diseases such as Netherton syndrome or AD, and that they do so by regulating SPINK5/LEKTI.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Lobelia chinensis Extract and Its Active Compound, Diosmetin, Improve Atopic Dermatitis by Reinforcing Skin Barrier Function through SPINK5/LEKTI Regulation
- Date Crossref
- 04/08/2022
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Bio-Medical Science (South Korea) pays non établi dans la noticeEntreprise
-
Korea Institute of Science and Technology pays non établi dans la noticeStructure de recherche
-
Korea University of Science and Technology KIST School pays non établi dans la noticeUniversité ou école supérieure
-
Pusan National University pays non établi dans la noticeUniversité ou école supérieure
-
Gachon University pays non établi dans la noticeUniversité ou école supérieure
-
Sookmyung Women's University pays non établi dans la noticeUniversité ou école supérieure
-
Natural Products Research Institute pays non établi dans la noticeStructure de recherche
-
College of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
College of Bio-Nano Technology Department of Life Science pays non établi dans la noticeUniversité ou école supérieure
Bio-Medical Science (South Korea), Korea Institute of Science and Technology et KIST School — Korea University of Science and Technology, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.